IDH1 and glioblastoma: Similarly, Bark et al. used microfluidic technology to isolate CTCs from newly diagnosed GBM patients (18/20 IDH wild-type), reporting that patients with zero CTC counts post-surgery experienced longer recurrence-free survival [18].